Walter M. Stadler
University of Illinois Chicago(US)University of Chicago(US)University of Chicago Medical Center(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Bladder and Urothelial Cancer Treatments, Renal and related cancers
Most-Cited Works
- → Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma(2007)4,772 cited
- → Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3(2016)1,550 cited
- → Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma(2018)1,227 cited
- → Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial(2009)1,079 cited
- → Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma(2006)1,030 cited
- → Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial